Table 1.
Demographic, surgical, and clinical data from elective spine patients screened for MRSA compared with those not screened for MRSA
| Data | Total | MRSA screened | MRSA screened 95% CI | Not MRSA screened | Not MRSA screened 95% CI |
|---|---|---|---|---|---|
| Number | 990 | 503 (50.8%) | (46.4%–55.2%) | 487 (49.2%) | (44.8%–53.6%) |
| Gender | |||||
| Male | 507 (51.2%) | 252 (50.1%) | (43.9%–56.3%) | 255 (52.4%) | (46.3%–58.5%) |
| Female | 483 (48.8%) | 251 (49.9%) | (43.7%–56.1%) | 232 (47.6%) | (41.2%–54.0%) |
| Age (years) | 57.0 ± 14.7 | 57.3 ± 14.0 | (56.1–58.5) | 56.9 ± 15.3 | (55.5–58.3) |
| BMI (kg/m2) | 30.0 ± 6.4 | 29.9 ± 6.7 | (29.3–30.5) | 30.1 ± 6.1 | (29.6–30.6) |
| Location | |||||
| Cervical | 255 (25.8%) | 145 (28.8%) | (21.4%–36.2%) | 110 (22.6%) | (14.8%–30.4%) |
| Thoracic | 26 (2.6%) | 12 (2.4%) | (−6.3% to 11.1%) | 14 (2.9%) | (−5.9% to 11.7%) |
| Lumbar | 709 (71.6%) | 346 (68.8%) | (63.9%–73.7%) | 363 (74.5%) | (70.0%–79.0%) |
| Primary | 708 (71.5%) | 350 (69.6%) | (64.8%–74.4%) | 358 (73.5%) | (68.9%–78.1%) |
| Revision | 282 (28.5%) | 153 (30.4%) | (23.1%–37.7%) | 129 (26.5%) | (18.9%–34.1%) |
| Instrumentation | 710 (71.7%) | 374 (74.4%) | (70.0%–78.8%) | 336 (69.0%) | (64.1%–73.9%) |
| Level of fusion | |||||
| 2 or less | 589 (59.5%) | 308 (61.2%) | (55.8%–66.6%) | 281 (57.7%) | (51.9%–63.5%) |
| 3 or more | 401 (40.5%) | 195 (38.8%) | (32.0%–45.6%) | 206 (42.3%) | (35.6%–49.0%) |
| Iliac crest bone autograft | 644 (65.1%) | 329 (65.4%) | (60.3%–70.5%) | 315 (64.7%) | (59.4%–70.0%) |
| Time to followup (days) | 201.5 (3–545) | 215.3 (3–545) | (206.0–224.6) | 187.3 (5–537) | (178.2–196.4) |
| Early wound complications | 34 (3.4%) | 17 (3.4%) | (−5.2% to 12.0%) | 17 (3.5%) | (−5.2% to 12.2%) |
| Wound drainage | 31 (3.1%) | 14 (2.8%) | (−5.8% to 11.4%) | 17 (3.5%) | (−5.2% to 12.2%) |
| Abscess | 3 (0.3%) | 3 (0.6%) | (−8.1% to 9.3%) | 0 (0%) | (0%–0%) |
| Perioperative antibiotics | |||||
| Cefazolin | 878 (88.7%) | 433 (86.1%) | (82.8%–89.4%) | 445 (91.4%) | (88.8%–94.0%) |
| Clindamycin | 35 (3.5%) | 18 (3.6%) | (−5.0% to 12.2%) | 17 (3.5%) | (−5.2% to 12.2%) |
| Vancomycin | 73 (7.4%) | 49 (9.7%) | (1.4%–18.0%) | 24 (4.9%) | (−3.7% to 13.5%) |
| Ciprofloxacin | 1 (0.1%) | 1 (0.2%) | (−8.6% to 9.0%) | 0 (0%) | (0%–0%) |
| Ceftriaxone | 2 (0.2%) | 2 (0.4%) | (−8.3% to 9.1%) | 0 (0%) | (0%–0%) |
CI = confidence interval, MRSA = methicillin-resistant Staphylococcus aureus; BMI = body mass index.